Abstract: Disclosed are (1) osteogenic devices comprising a matrix containing substantially pure natural-sourced mammalian osteogenic protein; (2) DNA and amino acid sequences for novel polypeptide chains useful as subunits of dimeric osteogenic proteins; (3) vectors carrying sequences encoding these novel polypeptide chains and host cells transfected with these vectors; (4) methods of producing these polypeptide chains using recombinant DNA technology; (5) antibodies specific for these novel polypeptide chains; (6) osteogenic devices comprising these recombinantly produced proteins in association with an appropriate carrier matrix; and (7) methods of using the osteogenic devices to mimic the natural course of endochondral bone formation in mammals.

Abstract: Methods for treating ocular conditions by inserting an implant comprising an active agent into an ocular site of a patient thereby obtaining an amelioration of a symptom of the ocular condition (i.e. a therapeutic effect) for an extended period of time during which a therapeutic amount or a detectable amount of the active agent is not present at the ocular site.

Abstract: Methods for treating ocular conditions by inserting an implant comprising an active agent into an ocular site of a patient thereby obtaining an amelioration of a symptom of the ocular condition (i.e. a therapeutic effect) for an extended period of time during which a therapeutic amount or a detectable amount of the active agent is not present at the ocular site.

Abstract: Methods for treating ocular conditions by inserting an implant comprising an active agent into an ocular site of a patient thereby obtaining an amelioration of a symptom of the ocular condition (i.e. a therapeutic effect) for an extended period of time during which a therapeutic amount or a detectable amount of the active agent is not present at the ocular site.

Abstract: This invention relates to films incorporating high amounts of pharmaceutical agents and methods for the preparation of the same. Moreover, the invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films contain a pharmaceutical and/or cosmetic active agent with no more than a 10% variance of the active agent pharmaceutical and/or cosmetic active agent per unit area of the film.

Abstract: The invention relates to polypeptides having glucanase, e.g., endoglucanase, mannanase, xylanase activity or a combination of these activities, and polynucleotides encoding them. In one aspect, the glucanase activity is an endoglucanase activity (e.g., endo-1,4-beta-D-glucan 4-glucano hydrolase activity) and comprises hydrolysis of 1,4-beta-D-glycosidic linkages in cellulose, cellulose derivatives (e.g., carboxy methyl cellulose and hydroxy ethyl cellulose) lichenin, beta-1,4 bonds in mixed beta-1,3 glucans, such as cereal beta-D-glucans or xyloglucans and other plant material containing cellulosic parts. In addition, methods of designing new enzymes and methods of use thereof are also provided. In alternative aspects, the new glucanases e.g., endoglucanases, mannanases, xylanases have increased activity and stability at increased pH and temperature.

Abstract: The invention relates to a composition comprising: (a) one or more aminoacids selected from glycine, proline and hydroxyproline; (b) a source of calcium ions; and (c) water. The invention also extends to a dry composition comprising the aforementioned components (a) and (b). The compositions of the invention are useful for arresting bleeding of humans and other animals, in particular for accelerating haemostasis at the site of incisions made during surgical procedures.

Abstract: A transdermal therapeutic system which is free of fibrous constituents, and a method for the production of such a transdermal therapeutic system A preparation containing active substance is applied by a printing method onto the pressure-sensitive adhesive layer of the transdermal therapeutic system.

Abstract: The present invention provides abuse-resistant transdermal delivery devices containing an opioid agonist intended for analgesic purposes in pain patients.

Abstract: A pharmaceutical composition for transdermal or transmucosal delivery of a pharmaceutical agent effective to treat a neurological disorder such as Parkinson's disease is disclosed. The composition contains an antioxidant, which provides color and chemical stability of the pharmaceutical agent. The antioxidant may also provide enhanced skin permeability of the agent.

Abstract: The present invention is directed to compositions and devices for transdermally administering vitamin B12 to a subject. In one aspect, a vitamin B12 containing composition suitable for transdermal administration is provided in the form of a shelf stable transdermal delivery patch. Such patches contain vitamin B12 combined with selected penetration enhancers and vitamin B12 stabilizers.

Abstract: The present invention relates to nanoparticle vaccine adjuvants comprised of a carrier, particularly polymerized lipids, having multiple copies of an antigen or combinations of different antigens displayed on the carrier. Such antigen-displaying nanoparticles may also display a targeting molecule on its surface in order to direct it to a specific site or cell type to optimize a desired immune response. The present invention also relates to encapsulating an antigen or combinations of different antigens within such nanoparticles, with or without a targeting molecule displayed on its surface. The antigens used in this invention are effective to produce an immune response against a variety of pathological conditions.

Abstract: The present invention relates to a method of protecting copper-sensitive compounds and/or compositions from decomposition.

Abstract: The present disclosure provides compositions suitable for delivering lipophilic bioactive agents. The compositions may be utilized to treat numerous diseases and conditions that would benefit from the application of a lipophilic bioactive agent.

Abstract: The present invention provides a unique package as well as methods packaging an enzyme portion and a substance portion. The package is bifurcated to maintain an enzyme separate from a primary substance until a predetermined set of environmental conditions is met. When the environmental conditions are met, the enzyme acts as a catalyst of the primary substance facilitating a change of the primary substance into a second substance. The environmental conditions can include, for example, conditions associated with a human alimentary canal.

Abstract: The present invention relates to the use of one or more fumaric acid derivatives as NF-kappaB inhibitor. At the same time, the present invention relates to the use of the fumaric acid derivatives for preparing a pharmaceutical composition for treating diseases that may be influenced by NF-kappaB.

Abstract: Various compounds can be administered orally to humans or animals for the purpose of enhancing nitric oxide production. Enhancing nitric oxide production is beneficial for those looking to increase lean body mass or enhance exercise performance. Such administration can also be used for the purpose of enhancing nutrient transport for purposes of athletic performance and controlling bodyweight and body fat levels. L-Arginine and alpha amino n-Butryate work synergistically to enhance nitric oxide production and may further be coupled with either and/or a) an inhibitor of nitric oxide breakdown or b) a nitric oxide potentiators or other precursor and serve to accomplish this goal of enhance nitric oxide. The composition may be administered in a variety of ways including capsules, tablets, powdered beverages, bars, gels or drinks.

Abstract: The invention concerns a method of production of a fine-crystalline mixture containing a non-steroid anti-inflammatory drug and an auxiliary substance, wherein a coarse-crystalline substance from the group of non-steroid anti-inflammatory drugs is dissolved in a solvent at an increased temperature, the solution is subsequently distributed at rapid chilling into a cooling liquid containing the auxiliary substance, said cooling liquid being placed in an ice bath, and the product is then filtered off and dried. It further concerns the fine-crystalline mixture of the non-steroid anti-inflammatory drug and the auxiliary substance that can be obtained by the said method. The invention further concerns a solid pharmaceutical composition, having substantially improved dissolution properties, which contains 60 to 78% w/w of the fine-crystalline mixture, 17 to 40% w/w of microcrystalline cellulose, colloidal silicon dioxide in an amount of up to 0.

Abstract: The invention relates to stable pharmaceutical compositions comprising the compound of the below formula, or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof.

Abstract: Accurate means of dosing with a compressed, segmented pharmaceutical tablet, and tablettes formed from said tablets, is disclosed.

Abstract: A pharmaceutical tablet adapted for accurate division of a dose of a drug into two or more smaller doses, which tablet has two or more segments.

Abstract: This invention is directed to the use of ranolazine to reduce the risk of adverse coronary events in a mammalian patient. Typically, the natriuretic peptide is associated with coronary disease, acute coronary syndrome, and/or diastolic dysfunction. Ranolazine may be administered to the patient as an intravenous solution or in an oral dose.

Abstract: The present disclosure relates to tablets obtainable by compression of a mixture comprising at least 5% by weight of a diluent and granules which comprise a very slightly soluble drug, wherein the granules consist of a core of saccharose beads having (prior to coating) a mean particle size greater than 150? and a coating layer comprising the very slightly soluble drug and at least one film-forming substance of high-molecular weight, as well as a process for manufacturing such tablets wherein the granules consist of a core saccharose beads having (prior to coating) a mean particle size greater than 150? and a coating layer comprising the very slightly soluble drug and at least one film-forming substance of high-molecular weight for the manufacture of tablets by compression of a mixture comprising said granules and at least 5% by weight of a diluent.

Abstract: The present invention relates to oral pharmaceutical compositions with controlled and/or programmed release containing at least one active ingredient having antimicrobial and/or anti-infectious activity for the treatment of infections of the large intestine, in particular the colon.

Abstract: Stabilized dispersions are provided for the delivery of a bioactive agent. The dispersions preferably comprise a plurality of perforated microstructures dispersed in a suspension medium that typically comprises a liquid fluorochemical. As density variations between the suspended particles and suspension medium are minimized and attractive forces between microstructures are attenuated, the disclosed dispersions are particularly resistant to degradation, such as by settling or flocculation. In particularly preferred embodiments the stabilized dispersions may be directly administered to the lung of a patient using an endotracheal tube or bronchoscope.

Abstract: The present invention concerns methods for stimulating the growth and repair of bone and cartilage using synthetic triterpenoids and tricyclic-bis-enones. Examples of suitable triterpenoids include CDDO, CDDO-Me, CDDO-Im, and CDDO-Ethylamide. Examples of tricyclic-bis-enones include TBE-31 and TBE-34.

Abstract: A sterile pharmaceutical composition having as its active principles piperacillin sodium and tazobactam sodium of substantially the same density, mixed with sodium bicarbonate. The mixture is soluble in water to give injectable reconstituted solutions having high stability with time.

Abstract: Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided.

Abstract: Micro-capsules for the slow release of drugs, consisting of a lactic-co-glycolic copolymer to which a plasticiser has been incorporated and which contain a drug of pharmaceutical interested within them.

Abstract: Methods of forming compositions for the sustained release of water soluble active agents, including biologically active polypeptides and products produced by the process are described. Improved product characteristics and ease of scale-up can be achieved using a novel coacervation process wherein at least one coacervation agent is added to the mixture comprising the active agent and the polymer in at least two distinct stages.

Abstract: The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular drug delivery.

Abstract: The invention relates to a method for preparing monodispersed biodegradable microspheres consisting in a) preparing an emulsion containing at least one polymeric phase and at least one aqueous phase at a viscosity ratio between the dispersed polymeric phase and the aqueous phase ranging from 0.12 to 10, b) exposing the thus obtained emulsion to a controlled laminar shear strength, c) removing a solvent from the polymeric phase and in d) isolating the thus obtained microspheres. The use of the prepared microspheres is also disclosed.

Abstract: The present invention relates to fungicidal compositions and particularly fungicidal compositions comprising anhydrous milk fat (AMF), soybean oil and/or coconut fat. The invention also relates to a fungicidal method employing a composition of the invention. The compositions and methods of the invention have applications in the management (prevention and control) of fungal growth in commercial and small scale crop production.

Abstract: A biomaterial comprising a porous biocompatible structure and a demineralized bone extract coated onto into the pores of the biocompatible structure are provided. The biomaterial may also comprise a demineralized bone gelatin where the gelatin may be coated over the extract coating or mixed with the extract coating before being applied to the biocompatible structure. Methods for making the biomaterial are also provided.

Abstract: An anti-microbial, solid architectural paint film produced by applying a liquid paint composition to a work surface, wall, ceiling or floor and allowing it to dry wherein the paint film comprises i) a film forming polymer and ii) an anti-microbial substance, comprising a metal or metal compound deposited on a particulate inorganic material, in an effective amount to kill microbes or prevent their growth on the surface of the solid coating and wherein the paint film is free of metallic copper and zinc and their alloys.

Abstract: A new, novel and useful disinfection and purification system comprised of organic compounds in synergistic action with selected metal ions and method of manufacture and use. One of the benefits that is derived from this system is the ability to quickly and easily treat a surface, fluid or medium for disinfection of bacteria, fungi, viruses, algae and protozoans, with a non-toxic, non-chlorinated mixture that effectively kills all such organisms in minutes or hours. The disinfection and purification system remains effective for long periods of time maintaining its disinfection capacity making it highly effective for stored or transported mediums such as potable drinking water. The disinfection and purification system may be incorporated with carbon block or membrane filters to disinfect filtered liquids such as water to render it potable.

Abstract: The present invention relates to an improved method for treating a wide range of inflammatory disorders by administering a tetracycline compound together with an effective inhibitor of tetracycline absorption, such as polyvalent metals. Pharmaceutical compositions used in that method are also taught.

Abstract: An aqueous solution suitable for injection into a mammal in need thereof includes an inorganic mercury (II) containing compound present in an amount between 0.1 nanomole and 50 millimoles Hg2+ where the solution is sufficiently stable such that there is no precipitation from the solution for at least thirty days of a visable precipitate containing at least some of said mercury. In one embodiment, a buffer which stabilizes the pH of the solution at a desired pH between 3.0 and 7.0 is provided. In another embodiment, at least one salt is provided in amounts which provide sufficient ionic strength to the solution and coordination ligand to prevent precipitation of the mercury from the solution.

Abstract: This invention relates to a use of the compound of formula (I), Erianin, in preparing pharmaceutical for treating tumors

Abstract: The present invention provides a method and composition for preventing, treating or managing Metabolic Syndrome. The composition contains brown marine vegetable extract containing an effective amount of fucoxanthin which is administered for preventing, treating or managing Metabolic Syndrome.

Abstract: Polymeric materials containing at least one continuous phase man-made polymer and at least one biodegradable component are protected against microbial attack through the use a combination of a boron-containing compound and an organic biocide. Methods and compositions for preparing treated polymeric materials are provided. A shaped article comprising a continuous phase man-made thermoplastic resin polymer, a biodegradable component, a boron-containing compound and an organic biocide is also provided.

Abstract: The present invention relates to a combined preparation comprising the active substance corticoid and a selenium-containing active substance. The combination of active substances leads to a clear reduction of the mortality rate of sepsis patients.

Abstract: The administration of gaseous nitric oxide as a biocidal moiety is proffered as a de novo treatment in the control and eradication of biofilms. The present invention relates to the use or methods of application of exogenous nitric oxide gas (gNO) as a stand alone biocidal agent or in cohort with any or all adjunct vehicles in the control of biofilms generated by microbial organisms, i.e., bacteria, protozoa, amoeba, fungi etc. Further, the present invention introduces the concept of utilization and methods of application of gaseous nitric oxide in control and eradication of biofilm forming microorganisms. Noteworthy areas of application are offered as examples. They include, and are not limited to, air and/or water heating/cooling distribution systems in facilities such as hospitals and laboratories, surfaces of medical devices, household surfaces, dental plaque, dental and/or medical water treatment lines, industrial pipelines, water treatment and distribution facilities and fluids sterilization.

Abstract: A multi-dimensional hair sustaining formulation having a liquid transport agent that carries multi-ingredients to hair follicles in order to prevent Dihydrotestosterone (DHT) from attaching to receptor sites on the follicles of existing hair, hence promoting the growth of existing hair which otherwise would succumb to DHT attack.

Abstract: The present invention relates to extracts and compounds which are isolated from Calomeria amaranthoides, and to derivatives and analogues of such compounds, which demonstrate cytotoxic activity against a variety of cell types exhibiting hyperproliferative cell division.

Abstract: An excipient and a method for manufacturing concentrated Chinese herbs through using the excipient are provided. The manufacturing method includes the following steps: (a) providing a Chinese herb raw material; (b) obtaining an extract from the Chinese herb raw material; (c) collecting volatile oils in a separate bin, later reintroduced; (d) removing water from the extract, to get a concentrate; and (e) adding an excipient to the concentrate, and then granulating and drying, to get a Chinese herbal preparation, in which the excipient contains a capsule protective agent of 1-99 wt % with respect to the excipient and a decomposed product of starch of 1-99 wt % with respect to the excipient. Therefore, the amount of starch required to be used is reduced and the manufactured concentrated Chinese herbal preparation can be completely dissolved in water.

Abstract: The extract of Siegesbeckiae herba of the present invention showed potent inhibitory effect on the dissociation of proteoglycan and type II collagen in chondrocyte and cartilage tissue and protecting effect on cartilage due to the inhibition of MMP-1, MMP-3 and MMP-13 activity and the restoring effect on cartilage tissue, the anti-inflammatory and antiphlogistic effect in edema animal model, anti-inflammatory effect confirmed by the inhibition test on PGE2 activity through COX-2 inhibition and the inhibition test of the reproduction of TNF-? and NO, it can be used as the therapeutics or health food for treating and preventing arthritic disease.

Abstract: The present invention relates to a composition comprising Notoginseng radix extract for preventing and treating arthritis as an effective ingredient. Notoginseng radix extract of the present invention inhibits release of tumor necrosis factor-alpha (TNF-?) and is the death of activated T-cells only, so that it can be effectively used for the production of a medicine for preventing and treating arthritis and health food as well.

Abstract: The inventive subject matter relates to methods for treating oral cancers, comprising administration of a composition comprising therapeutically effective amounts of supercritical extracts of rosemary, turmeric, oregano and ginger; and therapeutically effective amounts of hydroalcoholic extracts of holy basil, ginger, turmeric, Scutellaria baicalensis, rosemary, green tea, huzhang, Chinese goldthread, and barberry. The inventive subject matter further relates to methods for modulating gene expression of genes selected from the group consisting of interleukin-1?, interleukin-1?, heme oxygenase 1, aldo-keto reductase family 1, member C2, colony stimulating factor 3, leukemia inhibitory factor, heat shock 70 kDa protein, and combinations thereof, by administration of an effective amount of said compositions.

Abstract: The present invention provides a composition for diet comprising an essential oil adsorbent is coated with neroli oil to prepare an essential oil-coated particle, and then the particle is covered with a essential oil adsorbing and desorbing agent to prepare the carbon-coated particle (NR), the carbon-coated particle similarly prepared by using jasmin oil instead of neroli oil (JS), the carbon-coated particle similarly prepared by using rose oil instead of neroli oil (RO), and/or the carbon-coated particle similarly prepared by using cineol type Eucalyptus oil instead of neroli oil (CE), and the agent for diet comprising thereof as active ingredients. Accordingly, the agent for treating adipositas having high safety, of which composition ratio can be changed depending on a symptom of adipositas, is provided.